louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06957548: Cardiometabolic Disease Risk Factors in Cameroon
Official title: Screening for Cardiometabolic Disease Risk Factors: a Community Health Screening Program in Urban Cameroon
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Cardiac Disease
Metabolic Disease
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2025-05-04
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Urban Cameroon. Newbell, Douala, cameroon.

Brief summary: Cardiometabolic diseases (CMDs) are a major public health concern in sub-Saharan Africa, including Cameroon. Studies have shown a significant increase in the prevalence of hypertension, diabetes, and obesity in recent years. However, access to timely diagnosis and treatment remains limited, particularly in rural areas. Community-based screening programs have been shown to be effective in identifying individuals with undiagnosed CMD risk factors and promoting early intervention. By leveraging the strengths of community-based approaches, the URBACAM-D study aims to address the growing burden of CMDs in urban Cameroon.


Eligibility criteria: Inclusion Criteria:

* Screening is open to any adult over the age of 18 years

Primary outcomes:
measure: Prevalence of Cardiometabolic disease risk factors in Urban Cameroon
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Douala
country: Cameroon
facility: Newbell Protestant Hospital
state: Littoral
Study officials:
affiliation: Johns Hopkins University
name: Dimitri Tito, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05706948: High Intensity Interval Training on Cardiopulmonary Parameters With or Without Facemask in Healthy Participants
Official title: Effects of High Intensity Interval Training on Cardiopulmonary Parameters With or Without Facemask in Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-01-31
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To determine the effects of high intensity interval training on cardiovascular function, cardio metabolic markers and cardiorespiratory fitness in healthy individuals with or without facemask


Eligibility criteria: Inclusion Criteria:

* Non smoker
* Free of any heart and lung diseases
* Passed Physical Activity Readiness Questionnaire PAR-Q
* To be able to do exercise

Exclusion Criteria:

* Any physical limitation that restrict exercise
* Any neurological illness

Primary outcomes:
measure: Pulse
timeFrame: 4 weeks
measure: Oxygen saturation
timeFrame: 4 weeks
measure: Waist circumference
timeFrame: 4 weeks
measure: Modified BORG Scale
timeFrame: 4 weeks
measure: Vo2 Max
timeFrame: 4 weeks
measure: Body Mas Index
timeFrame: 4 weeks
measure: Hip circumference
timeFrame: 4 weeks
measure: Waist to hip ratio
timeFrame: 4 weeks
measure: Forced Expiratory Volume in 1 second (FEV1)
timeFrame: 4 weeks
measure: Forced vital Capacity (FVC)
timeFrame: 4 weeks
measure: Peak Expiratory Flow
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Islamabad Medical & Surgical Hospital
state: Fedral
Study officials:
affiliation: Riphah International University
name: Muhammad Iqbal Tariq, PhD*
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05833048: Rectus Sheath Block in Cardiac Surgery
Official title: Rectus Sheath Block in Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cardiac Disease
Postoperative Pain
Keywords: cardiac surgery
regional anesthesia
Lead sponsor: Icahn School of Medicine at Mount Sinai
Sponsor class: OTHER
First posted: 2023-04-27
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective, randomized study. The purpose of this study is to evaluate the effect of post-surgical pain control of a type of peripheral nerve block, Rectus Sheath Block.

1. Does the rectus sheath block decrease opioid consumption postoperatively after cardiac surgery?
2. Does the rectus sheath block decrease VAS pain scores postoperatively after cardiac surgery? Study participants will be assigned to receive either rectus sheath block or no block.


Eligibility criteria: Inclusion Criteria:

* In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Adults 18-85 years old
  2. Scheduled to undergo cardiac procedures involving chest tubes
  3. Male or female

Exclusion Criteria:

* An individual who meets any of the following criteria will be excluded from participation in this study:

  1. ASA class V
  2. Urgent or emergent surgery
  3. Contraindications to administration of local anesthesia (e.g. local anesthetic allergy)
  4. History of substance abuse or chronic opioid use
  5. Patient refusal or inability to consent

Primary outcomes:
measure: Opioid consumption
timeFrame: 72 hours postoperatively
measure: VAS pain scores
timeFrame: 72 hours postoperatively
Secondary outcomes:
measure: Length of stay in ICU
timeFrame: 72 hours
measure: Length of hospital stay
timeFrame: 72 hours
measure: Time to extubation
timeFrame: 72 hours
Other outcomes:
Locations:
city: New York
country: United States
facility: Mount Sinai Morningside Hospital Center
state: New York
Study officials:
References:
Clinical trial NCT05043948: Genome-wide Association Study of Development of Collateral Circulation for Patients With Coronary or Peripheral Artery Disease
Official title: Genome-wide Association Study of Development of Collateral Circulation for Patients With Coronary or Peripheral Artery Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Coronary Disease
Peripheral Arterial Disease
Collateral Circulation, Any Site
Keywords: Genome-wide association
Collateral circulation
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2021-09-14
Enrollment: 400
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with chronic total coronary or peripheral occlusion

Brief summary: The purpose of this study is to evaluate the genome-wide association for the development of collateral circulation for patients with coronary or peripheral artery disease and to develop the molecular genetic treatment model based on genome-wide association data.


Eligibility criteria: Inclusion Criteria:

* Age more than 20
* Chronic total occlusive lesion from the coronary or peripheral angiogram

Exclusion Criteria:

* Renal dysfunction
* Hepatic dysfunction
* Thrombocythemia or thrombocythemia
* Planned major surgery in 1 year
* History of gastrointestinal haemorrhage
* Malignant tumor

Primary outcomes:
measure: Correlation between genome and collateral flow
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
References:
Clinical trial NCT02754648: Three Different Laparoscopic Approaches for Ovarian Endometrioma and the Effect on Ovarian Reserve
Official title: Three Different Laparoscopic Approaches for Ovarian Endometrioma and the Effect on Ovarian Reserve
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Endometriosis
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2016-04-28
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Is ovarian reserve and fecundity rate higher with laparoscopic ovarian aspiration rather than laparoscopic ovarian cystectomy and laparoscopic ovarian de-roofing in infertile woman with ovarian endometrioma or not?

Detailed description: Primary objective:

To assess antral follicular count before and after treatment of endometriotic cyst either by aspiration, stripping, de-roofing and bed cauterization.

Secondary objectives To assess anti mullerian hormone level, follicle stimulating hormone level ,Doppler blood flow before and after treatment of endometriotic cyst either by aspiration, stripping, de-roofing and bed cauterization.

Eligibility criteria: Inclusion Criteria:

* Infertile woman aged 18-35 years old.
* Endometriotic ovarian cyst with size less than or equal 5 cm.

Exclusion Criteria:

* Other than included criteria.

Primary outcomes:
measure: The antral follicular count which records the number of visible ovarian follicle (2-10 mm mean diameter) seen by transvaginal ultrasound on menstrual cycle( days 2_5)
timeFrame: One month
Secondary outcomes:
measure: Anti mullerian hormone level in blood secreted by antral follicles 2-6 mm diameter in ovary
timeFrame: One month
measure: Follicle stimulating hormone in blood secreted by antral follicles on day 2-4 of menstrual cycle
timeFrame: One month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02689648: Long Term Follow up on Functional Gastrointestinal Disorder (FGID)
Official title: Long Term Follow up on Functional Gastrointestinal Disorder (FGID)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Functional Gastrointestinal Disorder
Lead sponsor: Umeå University
Sponsor class: OTHER
First posted: 2016-02-24
Enrollment: 400
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All children between 3 and 18 years of age that were refereed to the Pediatric Clinic of Västerbotten county council during the years 2009-2015.

Brief summary: Long term prognosis and risk factors in functional gastrointestinal disorder (FGID) is largely unknown. The investigators plan to retrospectively analyse a cohort of children who were referred to the Pediatric Clinic due to abdominal pain with the aims to learn more about symptoms and effects of investigations performed. Furthermore, the investigators plan to contact the cases for a follow up using a validated questionnaire and analyse the long term prognosis and risk factors for prolonged severe symptoms.

Detailed description: Long term prognosis and risk factors in functional gastrointestinal disorder (FGID) is largely unknown. The investigators plan to retrospectively analyse a cohort of children who during the years 2010-2015 were referred to the Pediatric Clinic of Umeå University Hospital due to abdominal pain. The aims are to explore and descriptively describe the symptoms and effects of investigations performed. Furthermore, the investigators plan to contact the cases five years after the first contact for a follow up using a validated questionnaire of the ROME-III-criteria and analyse the long term prognosis and risk factors for prolonged severe symptoms.

Eligibility criteria: At time of first visit the children had:

1. At least 2 months of abdominal pain
2. Age 3-18 years
3. No organic gastrointestinal diseases
4. No neuromuscular disease

Primary outcomes:
measure: Percentage (%) of patients that fulfill the ROME-III criteria for FGID
timeFrame: 5 years after fist visit +/- 1 year
Secondary outcomes:
measure: ICD 10-diagnosis following the primary investigation
timeFrame: 12 months after first visit
measure: Current ICD 10-diagnosis
timeFrame: 5 years after fist visit +/- 1 year
measure: Number (n) of visits for the primary investigations
timeFrame: 0-12 months after first visit
Other outcomes:
Locations:
city: Umeå
country: Sweden
facility: Umeå University, Department of Clinical Sciences
Study officials:
affiliation: Umeå University
name: Staffan K Berglund
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01801748: The Natural History of Wheat Hypersensitivity in Thai Children
Official title: The Natural History of Wheat Hypersensitivity in Thai Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Wheat Allergy
Child
Keywords: wheat allergy
wheat outgrowing
wheat hypersensitivity
omega-5-gliadin
natural history of wheat hypersensitivity
Lead sponsor: Mahidol University
Sponsor class: OTHER
Collaborators: name: National Research Council of Thailand
First posted: 2013-03-01
Enrollment: 43
Sex: ALL
Minimum age (years): 1
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Wheat allergy is affected 0.4-1% and is a major staple of the worldwide diet. Wheat avoidance is exceedingly difficult and imposes major dietary restriction. The purpose of this study were to determine the rate of oral tolerance and identify clinical and laboratory predictors of tolerance development in Thai children who allergic to wheat.

Detailed description: All children in this study were sensitized to wheat. Each patient was clinically evaluated, with focus on wheat allergy by both a detailed medical examination and collection of medical history. Blood sample was taken for baseline determination of ImmunoglobulinE antibodies to wheat and to omega-5-gliadin. The oral wheat challenge were performed in all study subjects to identify a case of wheat outgrowing. The primary outcome was the development of oral tolerance to wheat. Oral wheat challenge were generally performed at least every 1 years if the child did not have an interval history of symptoms with unintentional exposure.

Eligibility criteria: Inclusion Criteria:

* children 1 to 15 years
* History of IgE-mediated wheat allergy

Exclusion Criteria:

* Parents refused to sign the consent
* Patient has the underlying disease: congenital heart disease, uncontrolled asthma or life-threatening condition.

Primary outcomes:
measure: The number of participants who outgrow from wheat allergy
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Siriraj hospital
state: Bangkok
Study officials:
affiliation: Mahidol University
name: Punchama Pacharn, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00831948: Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.
Official title: Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mitochondrial Diseases
Diagnosis
DNA Mutations
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2009-01-29
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet detected by current diagnostic techniques

Brief summary: Mitochondrial diseases are a heterogeneous group caused by genetic defects in mitochondrial DNA or in nuclear genes. POLG is the most frequently involved gene in mtDNA instability diseases resulting in mtDNA multiple deletion and/or depletion. It encodes the DNA polymerase gamma (POLγ), the only known DNA polymerase found in mammalian mitochondria. Mutations in POLG could explain 45% of familial progressive external ophtalmoplegia associated with multiple mtDNA deletions. However, in more than 70%, the analysis of the genes involved in mtDNA instability remains unsuccessful.

To date, these genes are screened by sequencing methods that are not able to detect large-scale rearrangements. In order to detect possible large-scale rearrangements, the investigators propose to develop a new assay based on QMPSF (Quantitative Multiplex PCR of Short fluorescent Fragments) able to detect exon deletions and duplications. the investigators propose to screen the POLG gene by QMPSF in at least twenty patients with either no mutation or only one mutation detected in POLG and no mutation in other genes such as TWINKLE and ANT1.

This study would allow the investigators to know if large-scale rearrangements occur in the POLG gene and to estimate their frequency in patients with mtDNA instability. These data are important to know if the sequencing analysis of POLG should be completed by the screening for partial deletions and duplications to ensure an accurate molecular diagnosis of these syndromes. Moreover, this method could be extended to ANT1 and TWINKLE genes.


Eligibility criteria: Inclusion Criteria:

* Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet detected by current diagnostic techniques

Primary outcomes:
measure: Improving the diagnosis of mitochondrial pathology
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Nice
country: France
facility: Centre Hospitalier Universitaire de Nice- Hôpital ARCHET 2 -Laboratoire de Génétique Médicale
Study officials:
affiliation: Centre Hospitalier Universitaire
name: Cécile ROUZIER, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02044848: Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
Official title: A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Type 1 Diabetes Mellitus
Keywords: type 1 diabetes mellitus
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2014-01-24
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will assess the safety and efficacy of secukinumab on the preservation of pancreatic beta cells in patients with newly-diagnosed type 1 diabetes mellitus.


Eligibility criteria: Inclusion Criteria:

Males and females aged 18-35 years initially (subjects aged 8-17 may be included at a later stage, starting with age 12-17 years, followed by age 8-11 years).

Body weight between 40-120 kg initially (subjects weighing 21-39 kg may be included at a later stage).

Recent onset type 1 diabetes mellitus, diagnosed with 100 days of first dose. Peak stimulated C-peptide levels \>/= 0.2 pmol/L following mixed meal tolerance test

Exclusion Criteria:

Any form of diabetes other than auto-immune type 1 (eg, type 2 diabetes, maturity onset diabetes of the young, latent autoimmune diabetes of the adult).

Diabetic ketoacidosis within 2 weeks of screening. Pregnancy or lactation. Recent (within 2 weeks of screening), ongoing, chronic or recurrent infectious disease.

Active infection with hepatitis B or C, Epstein-Barr virus, cytomegalovirus, or HIV.

Tuberculosis infection. Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Stimulated C-peptide in Response to a Standard Mixed Meal Tolerance Test
timeFrame: Week 52
Secondary outcomes:
Other outcomes:
Locations:
city: New York City
country: United States
facility: Novartis Investigative Site
state: New York
city: Seattle
country: United States
facility: Novartis Investigative Site
state: Washington
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT06178848: EEG Parameters Between Remimazolam- and Propofol-based Anesthesia
Official title: Comparison of Quantitative EEG Parameters During Anesthesia Emergence Between Remimazolam Group and Propofol Group
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cholecystitis, Acute
Gallbladder Neoplasms
Acalculous Cholecystitis
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2023-12-21
Enrollment: 60
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This is an observational study comparing perioperative quantitative EEG parameters between the conventional propofol/remifentanil and remimazolam/remifentanil. We aim to compare and analyze the differences in EEG patterns during the postoperative recovery in a group that underwent remimazolam and remifentanil-based total intravenous anesthesia(TIVA), in comparison to propofol and remifentanil-based TIVA


Eligibility criteria: Inclusion Criteria:

Patients aged 19 to 65 years who meet the American Society of Anesthesiologists (ASA) physical status classification 1-3 and undergo laparoscopic cholecystectomy at Severance Hospital.

Exclusion Criteria:

Pregnant women, individuals with arrhythmias, emergency surgeries, obesity (BMI \> 30), day-surgery, foreigners, and illiterate individuals.

Primary outcomes:
measure: frontal spectral power
timeFrame: immediately after awakening at the end of the anesthesia, at post-anesthesia care unit (PACU)
Secondary outcomes:
measure: Riker sedation-agitation score
timeFrame: immediately after awakening at the end of the anesthesia, at post-anesthesia care unit (PACU)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine Yonsei University College of Medicine
Study officials:
affiliation: Department of Anesthesiology and Pain Medicine Yonsei University College of Medicine
name: Bon-Nyeo Koo
role: PRINCIPAL_INVESTIGATOR
References: